Phage microarray profiling of the humoral response to disease
The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides methods and compositions for phage microarray profiling of cancer (e.g., prostate, lung, or breast cancer). The present invention further provides novel markers useful for the diagnosis, characterization, and treatment of cancers.
1. A method comprising:
a) contacting a sample from a subject with a polypeptide comprising amino acid sequence SEQ ID NO: 403, 404, 83, 9, or 98; and
b) measuring a level of an autoantibody bound to the polypeptide.
2. The method of claim 1 , wherein the polypeptide is attached to a solid surface.
3. The method of claim 2 , wherein the solid surface is an array or a bead.
4. The method of claim 3 , wherein the solid surface is the array that is a microarray.
5. The method of claim 1 , wherein the polypeptide is displayed on a phage.
6. The method of claim 5 , wherein the phage is attached to a solid surface.
7. The method of claim 6 , wherein the solid surface is an array or a bead.
8. The method of claim 7 , wherein the solid surface is the array that is a microarray.
9. The method of claim 1 , further comprising diagnosing the subject with cancer based on the level of the autoantibody.
10. The method of claim 9 , wherein the polypeptide comprises amino acid sequence SEQ ID NO: 403, or 404, and wherein the cancer is prostate cancer.
11. The method of claim 9 , wherein the polypeptide comprises amino acid sequence SEQ ID NO: 83, 9, or 98, and wherein the cancer is lung cancer.
12. The method of claim 1 , further comprising providing a cancer prognosis based on the level of the autoantibody.
13. The method of claim 12 , wherein the polypeptide comprises amino acid sequence SEQ ID NO: 403, or 404, and wherein the cancer prognosis is a prostate cancer prognosis.
14. The method of claim 12 , wherein the polypeptide comprises amino acid sequence SEQ ID NO: 83, 9, or 98, and wherein the cancer prognosis is a lung cancer prognosis.
15. The method of claim 1 , further comprising selecting the subject for cancer therapy based on the level of the autoantibody.
16. The method of claim 15 , wherein the cancer therapy comprises radical prostatectomy, radiation treatment, hormone therapy, or a combination thereof.
17. The method of claim 1 , wherein the sample is a serum sample or a blood sample.
18. A method comprising,
a) contacting a sample from a subject with a polypeptide comprising an epitope derived from amino acid sequence SEQ ID NO: 403, 404, 83, 9, or 98; and
b) measuring a level of an autoantibody bound to the polypeptide.
19. The method of claim 18 , wherein the polypeptide is attached to a solid surface.
20. The method of claim 19 , wherein the solid surface is an array or a bead.
21. The method of claim 20 , wherein the solid surface is the array that is a microarray.
22. The method of claim 18 , wherein the polypeptide is displayed on a phage.
23. The method of claim 22 , wherein the phage is attached to a solid surface.
24. The method of claim 23 , wherein the solid surface is an array or a bead.
25. The method of claim 24 , wherein the solid surface is the array that is a microarray.
26. The method of claim 18 , further comprising diagnosing the subject with cancer based on the level of the autoantibody.
27. The method of claim 26 , wherein the polypeptide comprises the epitope derived from amino acid sequence SEQ ID NO: 403, or 404, and wherein the cancer is prostate cancer.
28. The method of claim 26 , wherein the polypeptide comprises the epitope derived from amino acid sequence SEQ ID NO: 83, 9, or 98, and wherein the cancer is lung cancer.
29. The method of claim 18 , further comprising providing a cancer prognosis based on the level of the autoantibody.
30. The method of claim 29 , wherein the polypeptide comprises the epitope derived from amino acid sequence SEQ ID NO: 403, or 404, and wherein the cancer prognosis is a prostate cancer prognosis.
31. The method of claim 29 , wherein the polypeptide comprises the epitope derived from amino acid sequence SEQ ID NO: 83, 9, or 98, and wherein the cancer prognosis is a lung cancer prognosis.
32. The method of claim 18 , further comprising selecting the subject for cancer therapy based on the level of the autoantibody.
33. The method of claim 32 , wherein the cancer therapy comprises radical prostatectomy, radiation treatment, hormone therapy, or a combination thereof.
34. The method of claim 18 , wherein the sample is a serum sample or a blood sample.